Cardiovascular Effects of Tricyclic Antidepressants in Childhood Asthma: A Case Series and Review

1997 ◽  
Vol 7 (1) ◽  
pp. 45-64 ◽  
Author(s):  
MARIANNE Z. WAMBOLDT ◽  
ASA G. YANCEY ◽  
THOMAS A. ROESLER
Keyword(s):  
Childhood Asthma ◽  
Tricyclic Antidepressants ◽  
Case Series ◽  
Cardiovascular Effects

Cannabis-associated arteritis

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen
Keyword(s):  
Systematic Review ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Causative Factor ◽  
Cannabis Use ◽  
Thromboangiitis Obliterans ◽  
Pathological Features ◽  
Scientific Support ◽  
Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.

Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart Disease

1982 ◽  
Vol 306 (16) ◽  
pp. 954-959 ◽  
Author(s):  
Richard C. Veith ◽  
Murray A. Raskind ◽  
James H. Caldwell ◽  
Robert F. Barnes ◽  
Gail Gumbrecht ◽  
...  
Keyword(s):  
Heart Disease ◽  
Tricyclic Antidepressants ◽  
Cardiovascular Effects ◽  
Depressed Patients ◽  
Chronic Heart Disease

scholarly journals Critically Ill Patients with Variable Heart Failure in Severe COVID-19 Disease: A Case Series

2021 ◽  
Vol 8 ◽  
Author(s):  
Joanne Michelle Gomez ◽  
Mary Potkonjak ◽  
Maria Isabel Planek ◽  
Prutha Lavani ◽  
Karolina Marinescu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Embolism ◽  
Early Diagnosis ◽  
Cardiogenic Shock ◽  
Critically Ill ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Massive Pulmonary Embolism ◽  
System Disorder ◽  
Obstructive Shock

COVID-19 disease, while primarily a respiratory disease, has proven itself a multi-system disorder with profound cardiovascular sequelae. In patients with SARS-CoV-2 infection, effective early diagnosis and management of concomitant cardiovascular manifestations of the disease are key to favorable outcomes. Here we present a case series of three patients with varied cardiovascular presentations of severe COVID-19 illness: cardiogenic shock from Takotsubo cardiomyopathy, arrhythmia in a patient with suspected hydroxychloroquine-associated cardiomyopathy, and right-sided heart failure with obstructive shock in the setting of massive pulmonary embolism. Through our experience, we aim to provide a better understanding of the unique spectrum of the cardiovascular effects of severe COVID-19 disease to guide management of the critically ill.

Cardiovascular Effects of Tricyclic Antidepressants

1987 ◽  
Vol 17 (5) ◽  
pp. 340-342 ◽  
Author(s):  
Alexander H Glassman ◽  
Steven P Roose
Keyword(s):  
Tricyclic Antidepressants ◽  
Cardiovascular Effects

Cardiovascular effects of the standard tricyclic antidepressants.

1988 ◽  
Vol 34 (5) ◽  
pp. 856-858 ◽  
Author(s):  
A H Glassman ◽  
R Pardell ◽  
S Woodring
Keyword(s):  
Tricyclic Antidepressants ◽  
Cardiovascular Effects

scholarly journals Association between Ophthalmic Timolol and Hospitalisation for Bradycardia

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Nicole L. Pratt ◽  
Emmae N. Ramsay ◽  
Lisa M. Kalisch Ellett ◽  
Tuan A. Nguyen ◽  
Elizabeth E. Roughead
Keyword(s):  
Beta Blocker ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Eye Drops ◽  
Continuous Exposure ◽  
Case Series Study ◽  
Increased Risk ◽  
Risk Period ◽  
Series Study ◽  
Remaining Time

Introduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation for bradycardia.Materials and Methods. A self-controlled case-series study was undertaken in patients who were hospitalised for bradycardia and were exposed to timolol. Person-time after timolol initiation was partitioned into risk periods: 1–30 days, 31–180 days, and >180 days. A 30-day risk period prior to initiating timolol was also included. All remaining time was considered unexposed.Results. There were 6,373 patients with at least one hospitalisation for bradycardia during the study period; 267 were exposed to timolol. Risk of bradycardia was significantly increased in the 31–180 days after timolol initiation (incidence rate ratio (IRR) = 1.93; 95% confidence interval (CI) 1.00–1.87). No increased risk was observed in the first 30 days or beyond 180 days of continuous exposure (IRR = 1.40; 95% CI 0.87–2.26 and IRR = 1.21; 95% CI 0.64–2.31, resp.).Conclusion. Bradycardia is a potential adverse event following timolol initiation. Practitioners should consider patient history before choosing a glaucoma regime and closely monitor patients after treatment initiation with topical nonselective beta-blocker eye drops.

Sign in / Sign up

Export Citation Format

Share Document